| Name | Title | Contact Details |
|---|
Wellteq is creating the future of precision wellness through a digital wellbeing ecosystem taking users from point of prevention through to point of care. Delivered into the corporate health and insurance sector to drive user engagement through a personalised wellness journey. wellteq uses a range of data types from wearable devices, sensors, biomarkers and user-generated data that, in combination with machine learning and artificial intelligence enables individual-level insights into Stress, Fatigue, Sleep Quality, Cognitive Function and Activity levels. Behavioural science and content targeting use biometric and behavioural analytics to deliver personalised wellness insights and practical recommendations to build engagement, agency and more effective sustainable management of personal wellness. Programs are highly customisable and provide an experience packed with gamification, group projects, social interaction rewards and charity all to maximise healthy behavioural change. With customisation comes flexibility, which is paramount for businesses of all shapes and sizes around the world today.
Ferring Pharmaceuticals is a private multinational biopharmaceutical company specialising in areas such as reproductive health, maternal health, gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years.
Capital City Nurses is a Chevy Chase, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.
Systemedic Rmi Inc is a Little Rock, AR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.